However, this may imply that screening for NAFLD or ALT testing is more likely when diabetes treatment is required (i.e., more advanced disease or drug-related liver monitoring) versus simply a diagnosis of diabetes. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.